We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Survey of Canadian Physician Use of Botulinum Toxin A (BoNT-A) for Paratonia: Real World Insights.
- Authors
Kleiner, Galit; Ismail, Farooq; Khan, Omar; Pilieci, Christopher; Truong, Linda; Boulias, Chris
- Abstract
Paratonia is a form of hypertonia characterized by an inability to relax muscles in the setting of cognitive impairment. Paratonia results in pain, refusal of care, and caregiver burden. We sent surveys to 67 Canadian physiatrists and neurologists regarding their experience treating paratonia with botulinum toxin A (BoNT-A). Twenty-seven survey respondents were included in the analysis. Thirteen percent of survey respondents treating paratonia with BoNT-A reported a significant clinically relevant improvement; 74% endorsed a moderately clinically relevant improvement; 13% endorsed a slight clinically relevant improvement. Ninety percent of survey respondents endorsed significant barriers in treating paratonia with BoNT-A.
- Subjects
BOTULINUM toxin; BOTULINUM A toxins; BURDEN of care; PHYSICIAN services utilization; COGNITION disorders
- Publication
Canadian Journal of Neurological Sciences, 2025, Vol 52, Issue 1, p141
- ISSN
0317-1671
- Publication type
Academic Journal
- DOI
10.1017/cjn.2024.46